Adagio Medical Q1 FY26 net loss narrows to $7 million; R&D expense falls to $2.7 million

Adagio Medical

Adagio Medical

ADGM

0.00
  • Adagio Medical posted a net loss of USD 7 million, narrowing from USD 7.7 million a year earlier; loss per share improved to USD 0.31 from USD 0.5.
  • Operating loss tightened to USD 5.2 million from USD 7.4 million, as research and development expense fell to USD 2.7 million from USD 3.7 million.
  • Selling, general and administrative expense dropped to USD 2.5 million from USD 3.5 million; cash and cash equivalents declined to USD 12.9 million from USD 17.1 million at Dec. 31, 2025.
  • FULCRUM-VT pivotal results showed 84% freedom from ICD shock at six months with 2.4% protocol-defined major adverse events; FDA IDE clearance expands the study to evaluate the next-generation vCLAS Ultra System.
  • CEO Todd Usen called the quarter “a landmark period,” citing “best-in-class safety” in FULCRUM-VT data with consistent outcomes across ischemic and non-ischemic cardiomyopathy patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260512085398) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.